Invest in MJ Blog

SAN DIEGO, May 18, 2015 (GLOBE NEWSWIRE) -- Cannabis has been illegal in Brazil – regardless of whether the origin is from marijuana or hemp. That has all changed thanks to two mothers, one in the United States and one in Brazil – and Real Scientific Hemp Oil™ (RSHO™), a Medical Marijuana, Inc.-marketed hemp product via its partnership with HempMeds Brasil™.

Medical Marijuana, Inc. (OTC Pink:MJNA) is proud to announce to shareholders and the public that HempMeds Brasil's™ RSHO™ product has been written into world history as the first cannabis product to be approved for import by Brazil's federal government and used as a prescription for approved medical indications within Brazil including epilepsy (CDKL5 and Dravet Syndrome). HempMeds Brasil™ is providing the RSHO™ exclusively for the Brazilian marketplace while under temporary broad approval for additional medical indications, subject to clinical trials within the country.

Today, any resident of Brazil who has a government-approved medical indication can have access to RSHO™ hemp oil products and may do so with both a doctor's prescription and government-approved import documentation. ANVISA has issued a statement on the agency's website, featuring a photo of a tube of RSHO™ from HempMeds Brasil™, and explains how to apply for an import certificate. Currently the product is approved via direct registration from an individual consumer, HempMeds Brasil™ has been working for over a year on its formal product drug application and submission. The company expects this to take through 2015 to complete.

May 29, 2015 - Medbox, Inc. (OTCQB: MDBX), a leading provider of specialized consulting and technology solutions to the legal marijuana industry, today announced that its wholly owned subsidiary, Vaporfection, has signed an exclusive North American distribution agreement for its “miVape” vaporizer with VaporNation, the largest wholesaler and online retailer of vaporizers.

The miVape vaporizer, which is expected to be available for purchase in June, is a self-contained, USB-rechargeable unit that uses medical grade, food-safe and heat resistant materials to deliver the healthiest experience possible.

“VaporNation is a symbiotic fit for Vaporfection as we introduce our portable, true convection miVape vaporizer to the market. I believe it is truly a game changer in terms of its high-quality construction, superior performance and strict adherence to safety standards,” said Dan Wynick, President of Vaporfection. “Aligning with VaporNation provides access to a robust distribution network as well as amazing marketing opportunities that will help us meet the demand for a high-caliber, portable vaporizer at an affordable price.”

LAS VEGAS, May 27, 2015 /PRNewswire/ -- DigiPath Labs, the cannabis testing subsidiary of DigiPath, Inc. (OTCQB: DIGPD) opened the doors of its Las Vegas marijuana analytical testing laboratory for business today. Equipped with state of the art analytical instrumentation and operated under the direction of Cindy Orser, PhD, DigiPath Lab's flagship facility offers cannabis growers and marijuana-based product-makers fast and reliable results.

"This is a great day for the patients of Nevada who will benefit from medical marijuana," said DigiPath Labs president Todd Denkin. "Our analysis not only helps product producers and dispensaries screen out products with dangerous levels of contaminants, we also quantify the medicinal compounds present in samples, so patients and caregivers can choose products that have been shown to relieve their specific symptoms."

Surprisingly, compulsory cannabis testing is relatively new. The State of Colorado only began requiring product testing a year ago after a series of overdoses on edibles made the news. Washington State did not begin requiring testing for potency, contaminants, moisture and microbiology testing until 2013 when recreational cannabis became legal, even though the medicinal use of marijuana became legal in 1998.

BOCA RATON, FL--(Marketwired - May 29, 2015) - Earth Science Tech, Inc. (OTCQB: ETST) ("ETST" or "the Company"), a unique biotechnology company focused on nutraceuticals, bioceuticals and dietary supplements, announces positive progress on its High Grade CBD (Cannabidiol) Rich Hemp Oil in vitro studies on various human primary cells with DV Biologics, a leading biological company. In order to assure the public that ETST provides the best High Grade CBD (Cannabidiol) Rich Hemp Oil, we continue to focus on providing the public with sound scientific research and keeping the public informed on the progression of studies being done on our Hemp CBD products. DV Biologics, which is independently testing our ETST High Grade Hemp CBD Oil in vitro on various human primary cells, has informed us of the progression of studies being done. The goals of these studies are to test if ETST High Grade CBD Rich Hemp Oil serves as a neuroprotectant which may help with neurodegenerative disorders.

"Testing compounds in vitro on human cells is difficult. We recently tested various concentrations of ETST High Grade CBD Hemp Oil on various cells to see which concentrations are toxic to cells and noted that the cells grow similarly in concentrations from 1-10 micromolar. This is exciting news as it shows that this product, ETST High Grade CBD Hemp Oil, may be used in varying concentrations without toxicity to different cell types. We are now ready to test whether ETST High Grade CBD Hemp Oil can stop or deter free radical formation that occurs in vitro with brain cells. In order to do so, we will use varying concentrations of ETST Hemp CBD Oil and induce oxidative stress on brain cells. We will then test the cells to see if the ETST Hemp CBD Oil reduces oxidative stress and free radical formation compared to a control cell type that has no ETST High Grade CBD Hemp Oil. We look forward to reporting the full study in the near future," stated Dr. Rafael Gonzalez, Vice President of Research & Development of DV Biologics.

SAN DIEGO, CA--(Marketwired - May 27, 2015) - MyDx, Inc., (OTC PINK: MYDX), the developer of MyDx™ (My Diagnostic), the first handheld chemical analyzer for consumers, has signed an exclusive patent sublicense agreement with Next Dimension Technologies, Inc. ("NDT"), a developer of electronic nose chemical sensing technology used by NASA, and funded by the Bill & Melinda Gates Foundation.

Under the agreement, NDT will license intellectual property relating to its chemical sensing technology that enables the MyDx Analyzer to sense, measure and report chemicals of interest to its customers. The company has exclusively licensed the use of the sensor technology to characterize and detect compounds in Cannabis.

"Offering the Cannabis Industry a friend in Science & Technology is an exciting step for MyDx," said Daniel Yazbeck, the company's Chairman & CEO. "We currently are the only company offering a practical Cannabis analysis solution at an affordable consumer price point. With this exclusive agreement, we now also have the intellectual property needed to further protect this competitive advantage."